Global pharmaceutical group Lotus strives to affirm its position in Southeast Asia

(Dan Tri) - As a prominent name in the global pharmaceutical industry, Lotus Multinational Pharmaceutical Company is present in over 70 countries and territories, actively affirming its position in the Southeast Asian market.

Development journey

In 1966, Lotus Pharmaceuticals, a multinational pharmaceutical company, established its first base in Taiwan (China). After more than half a century of continuous growth in size and capacity, in 2014, Lotus entered the potential Asian market through the merger with Alvogen.

Building on that momentum, in 2019, the company launched the P4 product in the US market, affirming its research and competitive capacity in the world's most demanding pharmaceutical market.

By 2021, with investment from PTT Thailand, Lotus will increase resources, expand research and business projects in the Southeast Asian market. In 2024, Lotus will continue to conduct M&A (mergers and acquisitions) deals in Thailand and Vietnam, enhancing its presence and distribution capacity in key markets.

Within 10 years, Lotus's revenue increased from 20 million USD to 500 million USD, equivalent to an increase of more than 2,400%, demonstrating a sustainable and effective development strategy.

Production capacity and broad development strategy

Lotus currently has over 250 commercial products for a wide range of therapeutic areas. The company operates three international GMP-certified factories and two R&D centers, ensuring strict manufacturing processes and consistent quality to help Lotus maintain its pioneering research capabilities.

With 1,400 global employees, including more than 450 sales and marketing personnel, Lotus manages a distribution network in more than 70 countries and territories, with Vietnam playing a key role in Lotus' expansion strategy in the Southeast Asian market.

Lotus focuses on a strategy of rapid expansion and sustainable development, with 5 pillars:

Wide presence across Asia- Pacific : With a network of offices and professional staff, Lotus quickly brings quality products closer to patients in key markets.

Diverse treatment portfolio: From pathology, neurology, nephrology, women's health to healthcare and lifestyle. Oncology and immunology are the focus, clearly demonstrating strategic direction and long-term investment commitment.

Strong cooperation network: Since 2019, Lotus has signed more than 265 cooperation agreements, bringing products to more than 160 countries and territories, and launching more than 30 new products.

Balanced product portfolio: A combination of original, generic, innovative and biosimilar drugs, ensuring both stability and breakthroughs in treatment.

Investing in in-depth research: Special focus on cancer treatment products with high technical barriers, while developing many other fields to meet increasingly diverse health care needs.

Lotus Pharmaceutical Company abroad (Photo: Lotus Pharmaceutical).

Based on extensive experience, research capacity and sustainable development strategy, Lotus affirms its position as a reliable partner in the pharmaceutical industry, bringing effective and accessible treatment solutions to the Southeast Asian market in general and Vietnam in particular.

In Vietnam, Lotus Multinational Pharmaceutical Company has had strategic cooperation plans such as receiving ownership of the brand and production line from Sanofi, applying pharmaceutical packaging technology with 5 superior protective layers to maintain the potency of active ingredients, meeting the storage conditions in tropical regions.

VN-NP-ALV-ALP-SMP-PNC-000002-10-22-2027

Source: https://dantri.com.vn/suc-khoe/tap-doan-duoc-pham-toan-cau-lotus-no-luc-khang-dinh-vi-the-tai-dong-nam-a-20251028163451228.htm